echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > $3.16 million in funding for the development of cancer immunotherapy drugs

    $3.16 million in funding for the development of cancer immunotherapy drugs

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A research team led by UTHSC received $3.


    Cancer immunotherapy is one of the hottest areas of personalized treatment, but unfortunately, many patients fail because of the cancer cells' ability to avoid and suppress the body's anti-tumor response


    "We were very surprised that our grant application received a perfect score


    Dr.


    Dr Steve Goodman, Vice-Chancellor for Research at UTHSC, said: "The development of the relationship between UTHSC and the Southern Research Centre, taking our joint CORNET Award as an example, is a very important step forward for UTHSC in developing drug discovery and development


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.